English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Background  This study aimed to explore parameters which will predict good control of HbA 1c  after adding a second anti-diabetic drug in patients with type 2 diabetes mellitus (T2DM) inadequately controlled with metformin monotherapy.    Methods  Fifty-one patients (M/F: 25/26, mean age: 53.7 ± 8.2 years, mean glycated hemoglobin [HbA 1c ] 8.4 ± 1.2%) with T2DM inadequately controlled with metformin were randomized to add-on glibenclamide or acarbose for 16 weeks. Before and after combination therapy, the subjects underwent a 2-hour liquid mixed meal tolerance test to determine insulin secretion (HOMA-β, insulinogenic index, and disposition index [DI]) and insulin sensitivity (HOMA-IR and Matsuda insulin sensitivity index).    Results  At baseline, there was a significant inverse relationship between DI 120  and HbA 1c  ( p  = 0.001) in all subjects. The addition of glibenclamide and acarbose improved HbA 1c  significantly from 8.6 ± 1.6% to 7.4 ± 1.2% ( p  < 0.001), and from 8.2 ± 0.8% to 7.5 ± 0.8% ( p  < 0.001), respectively. In the glibenclamide group, DI 120  significantly increased from 51.2 ± 24.2 to 74.9 ± 41.9 ( p  < 0.05), and in the acarbose group, from 62.5 ± 31.4 to 91.7 ± 36.2 ( p  < 0.05), respectively. Multiple regression analyses showed that both baseline HbA 1c  and DI 120  independently predicted reduction of HbA 1c  as well as final HbA 1c  after combination therapy.    Conclusions  In patients with T2DM inadequately controlled with metformin, add-on oral anti-diabetic agent with glibenclamide or acarbose resulted in the significant HbA 1c  reduction and improvement of β-cell function. Subjects with greater baseline β-cell function reserve displayed better glycemic response in the combination therapy of metformin with glibenclamide or acarbose.    Trial registration  This study was registered in the ClinicalTrials.gov with registration number of  NCT00417729 .

diabetology and metabolic syndrome

Post-meal β-cell function predicts the efficacy of glycemic control in patients with type 2 diabetes inadequately controlled by metformin monotherapy after addition of glibenclamide or acarbose